flutamide
Tradename Eulexin
Manufacturer Schering
Treatment Class Endocrine and metabolic
Indication Metastatic prostatic carcinoma
MSB Review: Focus On... The Prostate
Med-Brief: Flutamide and Surgical Removal of Testes: Effect on Survival
Rate of Metastatic Prostate Cancer Patients - Oct 98
Med-Brief: Post-castration Drug Therapy in Advanced Prostate Cancer
Patients - Nov 98
gemcitabine
Tradename Gemzar
Manufacturer Lilly
Treatment Class Oncology
Indication Pancreatic cancer
MSB Review: Gemcitabine Approved for Pancreatic Cancer
MSB Review: Topotecan Approved for Ovarian Cancer
PNN Review Breast Cancer Symposium Opens in San Antonio
gemcitabine
Tradename Gemzar
Manufacturer Lilly
Treatment Class Oncology
Indication Pancreatic cancer
MSB Review: Gemcitabine Approved for Pancreatic Cancer
MSB Review: Topotecan Approved for Ovarian Cancer
PNN Review Breast Cancer Symposium Opens in San Antonio
granisetron
Tradename Kytril
Manufacturer SmithKline Beecham
Treatment Class Psychopharmacologic and Neurologic (CNS)
Indication Chemotherapy-induced vomiting
MSB Review: Granisetron Approved for Chemotherapy-induced Vomiting
MSB Review: Oral Granisetron Antiemetic for High-dose Chemotherapy
MSB Review: Oral Ondansetron Indication Expanded to Post-Op Nausea and
Vomiting
MSB Review: Dolasetron for Chemotherapy-induced Nausea
irinotecan
Tradename Campto, Camptosar
Manufacturer Rhone-Poulenc Rorer Inc., Pharmacia & Upjohn
Treatment Class Oncology
Indication Advanced colorectal cancer
DrugPR: STUDIES DEMONSTRATE HIGH ACTIVITY OF CAMPTO(R) AS TREATMENT FOR
COLORECTAL CANCER
DrugPR: FDA APPROVAL OF COLORECTAL CANCER TREATMENT -- FIRST TO BE BASED ON
SURVIVAL DATA - October 23, 1998
MSB Review: Topotecan Approved for Ovarian Cancer
MSB Review: Irinotecan Approved for Advanced Colorectal Cancer
Med-Brief: Drug Treatment of Advanced Colorectal Cancer - Nov 98
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
